U.S. markets close in 1 hour 59 minutes
  • S&P 500

    4,416.97
    +5.18 (+0.12%)
     
  • Dow 30

    35,115.85
    +54.30 (+0.15%)
     
  • Nasdaq

    14,829.25
    -7.75 (-0.05%)
     
  • Russell 2000

    2,211.22
    +1.58 (+0.07%)
     
  • Crude Oil

    71.90
    -0.17 (-0.24%)
     
  • Gold

    1,798.50
    -3.30 (-0.18%)
     
  • Silver

    25.30
    +0.07 (+0.27%)
     
  • EUR/USD

    1.1815
    +0.0044 (+0.38%)
     
  • 10-Yr Bond

    1.2710
    -0.0150 (-1.17%)
     
  • GBP/USD

    1.3823
    +0.0069 (+0.50%)
     
  • USD/JPY

    110.3320
    -0.1780 (-0.16%)
     
  • BTC-USD

    39,218.84
    +4,793.64 (+13.92%)
     
  • CMC Crypto 200

    934.28
    +18.79 (+2.05%)
     
  • FTSE 100

    7,025.43
    -2.15 (-0.03%)
     
  • Nikkei 225

    27,833.29
    +285.29 (+1.04%)
     

Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to give a presentation at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 11:30 a.m. ET. Dr. Bolno will provide a corporate update and discuss Wave’s pipeline programs, including the first in vivo data from the company’s ADAR editing discovery program for alpha-1 antitrypsin deficiency (AATD).

A live webcast of the presentation will be available on the investor relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com. A replay of the presentation will be archived and available at that site for 90 days following the event.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contact:
Kate Rausch
617-949-4827
krausch@wavelifesci.com

Media Contact:
Alicia Suter
617-949-4817
asuter@wavelifesci.com